Zomedica Pharmaceuticals Corp (CVE:ZOM) traded up 69.2% on Thursday . The stock traded as high as C$0.55 and last traded at C$0.55. 116,904 shares were traded during trading, an increase of 995% from the average session volume of 10,672 shares. The stock had previously closed at C$0.33.
Separately, HC Wainwright reiterated a “buy” rating on shares of Zomedica Pharmaceuticals in a research report on Wednesday, June 5th.
The stock has a market cap of $46.46 million and a price-to-earnings ratio of -1.15.
Zomedica Pharmaceuticals (CVE:ZOM) last announced its quarterly earnings results on Friday, May 10th. The company reported C($0.16) earnings per share for the quarter.
COPYRIGHT VIOLATION NOTICE: “Zomedica Pharmaceuticals (CVE:ZOM) Trading 69.2% Higher” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2019/06/13/zomedica-pharmaceuticals-cvezom-trading-69-2-higher.html.
Zomedica Pharmaceuticals Company Profile (CVE:ZOM)
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies.
Featured Story: Call Option
Receive News & Ratings for Zomedica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.